Xylopropamine

Stimulant drug of the phenethylamine and amphetamine classes
  • none
Legal statusLegal status
  • CA: Schedule I
  • UK: Class B
  • US: Schedule I (positional isomer of Etilamfetamine)
  • In general: ℞ (Prescription only)
Identifiers
  • (±)-1-(3,4-dimethylphenyl)propan-2-amine
CAS Number
  • 102-31-8 ☒N
  • Sulfate: 14543-76-1 ☒N
PubChem CID
  • 26727
ChemSpider
  • 24901 ☒N
UNII
  • 4DB10V9J2I
  • Sulfate: B464QNG39U ☒N
CompTox Dashboard (EPA)
  • DTXSID70904041 Edit this at Wikidata
Chemical and physical dataFormulaC11H17NMolar mass163.264 g·mol−13D model (JSmol)
  • Interactive image
ChiralityRacemic mixture
  • c1c(ccc(c1C)C)CC(N)C
InChI
  • InChI=1S/C11H17N/c1-8-4-5-11(6-9(8)2)7-10(3)12/h4-6,10H,7,12H2,1-3H3 ☒N
  • Key:ZSZUWPRERIPUBM-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Xylopropamine (Perhedrin, Esanin), also known as 3,4-dimethylamphetamine, is a stimulant drug of the phenethylamine and amphetamine classes which was developed and marketed as an appetite suppressant in the 1950s.[1]

Xylopropamine was briefly sold as the sulfate salt, but it was not widely marketed. Other related amphetamine derivatives such as 2,4-dimethylamphetamine were also investigated for the same purpose, however these drugs had negative side effects such as high blood pressure and were not very successful, mainly due to the introduction of alternative drugs like phentermine which had similar efficacy but fewer side effects.

Xylopropamine was also reported as having analgesic[2] and anti-inflammatory[3] effects but its side effect profile resulted in it never being further developed for these applications.

See also

References

  1. ^ US 2384700, Schnider O, "Alkylated phenyl-isopropyl-amines and process for the manufacture of same", issued 11 September 1945, assigned to Hoffman La Roche 
  2. ^ Harris SC, Worley RC (June 1957). "Analgesic properties of xylopropamine". Proceedings of the Society for Experimental Biology and Medicine. 95 (2): 212–5. doi:10.3181/00379727-95-23170. PMID 13441687. S2CID 34027366.
  3. ^ Randall LO, Selitto JJ, Valdes J (December 1957). "Anti-inflammatory effects of xylopropamine". Archives Internationales de Pharmacodynamie et de Therapie. 113 (1–2): 233–49. PMID 13509788.
  • v
  • t
  • e
AdamantanesAdenosine antagonistsAlkylaminesAmpakinesArylcyclohexylaminesBenzazepinesCathinonesCholinergicsConvulsantsEugeroicsOxazolinesPhenethylamines
PhenylmorpholinesPiperazinesPiperidinesPyrrolidinesRacetamsTropanesTryptaminesOthers
  • v
  • t
  • e
Stimulants
Amphetamines and
phenethylamines
Adrenergic agonists
Other
Cannabinoid
antagonists
GLP-1, GIP, and / or
glucagon agonists
DACRAs
5-HT2C
receptor agonists
Absorption inhibitors
Uncouplers
Others
  • v
  • t
  • e
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
  • v
  • t
  • e
Phenethylamines


Stimulants: Phenylethanolamine

Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
Phenylalkylpyrrolidines
Catecholamines
(and close relatives)
Miscellaneous